Organigram Global Inc. SEC filings OGI
Organigram Global Inc. has 321 filings in SEC EDGAR's recent list, going back to Apr 13, 2015. Its latest annual report, Form 40-F, was filed on Dec 16, 2025 for the period ended Sep 30, 2025. The most recent current report (Form 6-K) was filed on Nov 3, 2026. The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| SUPPL | Form suppl | Mar 28, 2024 | — |
| CT ORDER | Filing | Mar 1, 2024 | — |
| EFFECT | Filing | Nov 29, 2023 | — |
| CT ORDER | Filing | May 3, 2023 | — |
| SUPPL | Form suppl | Dec 19, 2022 | — |
| EFFECT | Filing | Nov 17, 2021 | — |
| D | Filing | Mar 25, 2021 | — |
| SUPPL | Form suppl | Nov 10, 2020 | — |
| SUPPL | Form suppl | Apr 22, 2020 | — |
| SUPPL | Filing | Dec 4, 2019 | — |
| EFFECT | Filing | Nov 27, 2019 | — |
| D | Filing | Jul 3, 2019 | — |
| CERT | Filing | May 13, 2019 | — |
| 40FR12B | Form 40fr12b | Apr 29, 2019 | — |
| D | Filing | Sep 1, 2016 | — |
| D/A | Filing | Jul 21, 2016 | — |
| D | Filing | Jun 17, 2016 | — |
| D | Filing | Dec 8, 2015 | — |
| D | Filing | Apr 13, 2015 | — |
| D | Filing | Apr 13, 2015 | — |
Showing 20 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OGI (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Toronto
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1620737
- Former names
- ORGANIGRAM HOLDINGS INC. (until Apr 1, 2025); ORGANIGRAM HOLDINGS INC (until Jul 21, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.